Risk factors of non-Hodgkin's lymphoma

Expert Opinion on Medical Diagnostics

Volumn 5, Issue 6, 2011, Pages 539-550

  Zhang, Yawei ^a   Dai, Ying ^a   Zheng, Tongzhang ^a   Ma, Shuangge ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

Bioinformatics analysis; Etiology; NHL; Prognosis; Risk factors

Indexed keywords

BIOINFORMATICS; CANCER CLASSIFICATION; CANCER RISK; CLINICAL FEATURE; CLINICAL PRACTICE; ENVIRONMENTAL FACTOR; GENETIC RISK; HUMAN; IMMUNOPHENOTYPING; NONHODGKIN LYMPHOMA; PROGNOSIS; REVIEW; RISK FACTOR; STATISTICAL PARAMETERS;

EID: 80054892862     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2011.618185     Document Type: Review

References (100)

1. Eltom MA, Jemal A, Mbulaiteye SM, et al. Trends in kaposis sarcoma and Non-Hodgkins lymphoma incidence in the united states from 1973 through 1998. J Natl Cancer Inst 2002;5:1204-10 (Pubitemid 34993870)
2. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975 - 2008. National Cancer Institute, Bethesda, MD; based on November 2010 SEER data submission
3. Aisenberg AC. Historical review of lymphomas. Br J Haematol 2000;109:466-76 (Pubitemid 30415169)
4. Cogliatti SB, Schmid U. Who is WHO and what was REAL? Swiss Med Wkly 2002;132:607-17
5. Jaffe ES, Harris NL, Stein H, et al. Organization classification of tumours/ pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press; Lyon, France: 2001
6. Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by who subtype in the United States, 1992 - 2001. Blood 2006;107:265-76 (Pubitemid 43053551)
7. Morton LM, Wang SS, Cozen W, et al. Etiologic heterogeneity among Non-Hodgkin Lymphoma subtypes. Blood 2008;15:5150-60
8. Hartge P, Wang SS, Bracci PM, et al. Non-Hodgkin Lymphoma. In: Schottenfeld D, Fraumeni JFJ. editors. Cancer epidemiology and prevention. Oxford University Press; New York: 2006. p. 898-918
9. Morton LM, Hartge P, Holford TR, et al. Cigarette smoking and risk of non-Hodgkin lymphoma: a pooled analysis from the international lymphoma epidemiology consortium (InterLymph). Cancer Epidemiol Biomarkers Prev 2005;14:925-33 (Pubitemid 40478558)
10. Morton LM, Zheng T, Holford TR, et al. Alcohol consumption and risk of non-Hodgkin lymphoma: a pooled analysis. Lancet Oncol 2005;6:469-76 (Pubitemid 40903627)
11. Zhang Y, Sanjose SD, Bracci PM, et al. Personal use of hair dye and the risk of certain subtypes of non-Hodgkin lymphoma. Am J Epidemiol 2008;167:1321-31 (Pubitemid 351770553)
12. Hughes AM, Armstrong BK, Vajdic CM, et al. Sun exposure may protect against non-Hodgkin lymphoma: a case-control study. Int J Cancer 2004;112:865-71 (Pubitemid 39435273)
13. Smedby KE, Hjalgrim H, Melbye M, et al. Ultraviolet radiation exposure and risk of malignant lymphomas. J Natl Cancer Inst 2005;97:199-209 (Pubitemid 40277370)
14. Zhang Y, Holford TR, Leaderer B, et al. Ultraviolet radiation exposure and risk of non-Hodgkins lymphoma. Am J Epidemiol 2007;165:1255-64 (Pubitemid 47234328)
15. Kricker A, Amstrong BK, Hughes AM, et al. Personal sun exposure and risk of non-Hodgkin lymphoma: a pooled analysis form the InterLymph Consortium. Int J Cancer 2008;122:144-54 (Pubitemid 350209989)
16. Willett EV, Morton LM, Hartge P, et al. Non-Hodgkin lymphoma and obesity: a pooled analysis from the InterLymph Consortium. Int J Cancer 2008;122:2062-70 (Pubitemid 351441197)
17. Larsson SC, Wolk A. Body mass index and risk of non-Hodgkins lymphoma: a meta-analysis of prospective studies. Eur J Cancer 2011; [Epub ahead of print]
18. Dryver E, Brandt L, Kauppinen T, et al. Occupational exposures and non-Hodgkins lymphoma in Southern Sweden. Int J Occup Environ Health 2004;10:13-21 (Pubitemid 40287946)
19. Kato I, Koenig KL, Watanabe-Meserve H, et al. Personal and occupational exposure to organic solvents and risk of non-Hodgkins lymphoma (NHL) in women (United States). Cancer Causes Control 2005;16:1215-24 (Pubitemid 46179505)
20. Fritschi L, Benke G, Hughes AM, et al. Risk of non-Hodgkin lymphoma associated with occupational exposure to solvents, metals, organic dusts and PCBs (Australia). Cancer Causes Control 2005;16:599-607 (Pubitemid 40933631)
21. Vineis P, Miligi L, SenioriCostantini A. Exposure to solvents and risk of non-Hodgkin lymphoma: clues on putative mechanisms. Cancer Epidemiol Biomarkers Prev 2007;16:381-4 (Pubitemid 46548636)
22. Miligi L, Costantini AS, Benvenuti A, et al. Occupational exposure to solvents and the risk of lymphomas. Epidemiology 2006;17:552-61 (Pubitemid 44223064)
23. Cocco P, tMannetje A, Fadda D, et al. Occupational exposure to solvents and risk of lymphoma subtypes: results from the Epilymph case-control study. Occup Environ Med 2010;67:341-7
24. Wang R, Zhang Y, Lan Q, et al. Occupational exposure to solvents and risk of non-Hodgkin lymphoma in Connecticut women. Am J Epidemiol 2009;169:176-85
25. Viel JF, Floret N, Deconinck E, et al. Increased risk of non-Hodgkin lymphoma and serum organochlorine concentrations among neighbors of a municipal solid waste incinerator. Environ Int 2011;37:449-53
26. Bertrand KA, Spiegelman D, Aster JC, et al. Plasma organochlorine levels and risk of non-Hodgkin lymphoma in a cohort of men. Epidemiology 2010;21:172-80
27. Laden F, Bertrand KA, Altshul L, et al. Plasma organochlorine levels and risk of non-Hodgkin lymphoma in the Nurses Health Study. Cancer Epidemiol Biomarkers Prev 2010;19:1381-4
28. Cocco P, Brennan P, Ibba A, et al. Plasma polychlorobiphenyl and organochlorine pesticide level and risk of major lymphoma subtypes. Occup Environ Med 2008;65:132-40 (Pubitemid 351211990)
29. Chang ET, Balter LM, Torrang A, et al. Nutrient intake and risk of non-Hodgkins lymphoma. Am J Epidemiol 2006;164:1222-32 (Pubitemid 44950390)
30. Zheng T, Holford TR, Leaderer B, et al. Diet and nutrient intakes and risk of non-Hodgkins lymphoma in Connecticut women. Am J Epidemiol 2004;159:454-66 (Pubitemid 38280291)
31. Lim U, Wang SS, Hartge P, et al. Gene-nutrient interactions among determinants of folate and one-carbon metabolism on the risk of non-Hodgkin lymphoma: NCI-SEER case-control study. Blood 2007;109:3050-9 (Pubitemid 46482106)
32. Skibola CF, Nieters A, Bracci PM, et al. A functional tnfrsf5 gene variant is 2008;111:4348-54
33. Lan Q, Zheng T, Chanock S, et al. Genetic variants in caspase genes and susceptibility to non-Hodgkin lymphoma. Carcinogenesis 2007;28:823-7 (Pubitemid 46523339)
34. Lan Q, Zheng T, Shen M, et al. Genetic polymorphisms in the oxidative stress pathway and susceptibility to non-Hodgkin lymphoma. Hum Genet 2007;121:161-8 (Pubitemid 46404450)
35. Rothman N, Skibola CF, Wang SS, et al. Genetic variation in tnf and il10 and risk of non-Hodgkin lymphoma: a report from the Interlymph consortium. Lancet Oncol 2006;7:27-38 (Pubitemid 43025390)
36. Nieters A, Beckmann L, Deeg E, et al. Gene polymorphisms in toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk. Genes Immun 2006;7:615-24 (Pubitemid 46242365)
37. Purdue MP, Lan Q, Wang SS, et al. A pooled investigation of Toll-like receptor gene variants and risk of non-Hodgkin lymphoma. Carcinogenesis 2009;30:275-81
38. Cerhan JR, Ansell SM, Fredericksen ZS, et al. Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma. Blood 2007;110:4455-63 (Pubitemid 351377812)
39. Sauer H, Wartenberg M, Hescheler J. Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cell Physiol Biochem 2001;11:173-86 (Pubitemid 32786086)
40. Lightfoot TJ, Skibola CF, Smith AG, et al. Polymorphisms in the oxidative stress genes, superoxide dismutase, glutathione peroxidase and catalase and risk of non-Hodgkins lymphoma. Haematologica 2006;91:1222-7 (Pubitemid 44408432)
41. Chaganti RS, Nanjangud G, Schmidt H, et al. Recurring chromosomal abnormalities in non-Hodgkins lymphoma: biologic and clinical significance. Semin Hematol 2000;37:396-411
42. Shen M, Purdue MP, Kricker A, et al. Polymorphisms in DNA repair genes and risk of non-Hodgkins lymphoma in New South Wales, Australia. Haematologica 2007;92:1180-5 (Pubitemid 350144175)
43. Nauss KM, Newberne PM. Effects of dietary folate, vitamin b12 and methionine/choline deficiency on immune function. Adv Exp Med Biol 1981;135:63-91
44. Kim HN, Lee IK, Kim YK, et al. Association between folate-metabolizing pathway polymorphism and non-Hodgkin lymphoma. Br J Haematol 2008;140:287-94
45. Conde L, Halperin E, Akers NK, et al. Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet 2010;42:661-4
46. Smedby KE, Foo JN, Skibola CF, et al. GWAS of follicular lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma. PLoS Genet 2011;7:e1001378
47. A predictive model for aggressive non-Hodgkins lymphoma. The international non-Hodgkins lymphoma prognostic factors project. N Engl J Med 1993;329:987-94
48. Battaglioli T, Gorini G, Costantini AS, et al. Cigarette smoking and alcohol consumption as determinants of survival in non-Hodgkins lymphoma: a population-based study. Ann Oncol 2006;17:1283-9 (Pubitemid 44288219)
49. Geyer SM, Morton SM, Habermann TM, et al. Smoking, alcohol use, obesity, and overall survival from non-Hodgkin lymphoma: a population-based study. Cancer 2010;116:2993-3000
50. Talamini R, Polesel J, Spina M, et al. The impact of tobacco smoking and alcohol drinking on survival of patients with non-Hodgkin lymphoma. Int J Cancer 2008;122:1624-9 (Pubitemid 351294973)
51. Bell DA, Liu Y, Cortopassi GA. Occurrence of bcl-2 oncogene translocation with increased frequency in the peripheral blood of heavy smokers. J Natl Cancer Inst 1995;87:223-4
52. Lococo F, Gaidano G, Louie DC, et al. P53 mutations are associated with histologic transformation of follicular lymphoma. Blood; 1993: 82: 2289-95 (Pubitemid 23304250)
53. Han X, Zheng T, Foss FM, et al. Alcohol consumption and non-Hodgkin lymphoma survival. J Cancer Surviv 2010;4:101-9
54. Diaz LE, Montero A, Gonzalez-gross M, et al. Influence of alcohol consumption on immunological status: a review. Eur J Clin Nutr 2002;56(Suppl 3):s50-3
55. Tarella C, Caracciolo D, Gavarotti P, et al. Overweight as an adverse prognostic factor for non-Hodgkins lymphoma patients receiving high-dose chemotherapy and autograft. Bone Marrow Transplant 2000;26:1185-91
56. El-Far M, Fouda M, Yahya R, El-Baz H. Serum il-10 and il-6 levels at diagnosis as independent predictors of outcome in non-Hodgkins lymphoma. J Physiol Biochem 2004;60:253-8 (Pubitemid 40775120)
57. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large b-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11 (Pubitemid 30082188)
58. Lossos IS, Alizadeh AA, Rajapaksa R, et al. Hgal is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large b-cell lymphoma. Blood 2003;101:433-40 (Pubitemid 36077560)
59. Lossos IS, Jones CD, Warnke R, et al. Expression of a single gene, bcl-6, strongly predicts survival in patients with diffuse large b-cell lymphoma. Blood 2001;98:945-51
60. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large b-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68-74 (Pubitemid 34101731)
61. Rosenwald A, Wight G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-b-cell lymphoma. N Engl J Med 2002;346:1937-47 (Pubitemid 34651353)
62. Horsman DE, Connors JM, Pantzar T, et al. Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14;18). Genes Chromosomes Cancer 2001;30:375-82 (Pubitemid 32216328)
63. Yunis JJ, Frizzera G, Oken MM, et al. Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer. N Engl J Med 1987;316:79-84 (Pubitemid 17052742)
64. Eray M, Postila V, Eeva J, et al. Follicular lymphoma cell lines, an in vitro model for antigenic selection and cytokine-mediated growth regulation of germinal centre b cells. Scand J Immunol 2003;57:545-55 (Pubitemid 36734994)
65. Bohen SP, Troyanskaya OG, Alter O, et al. Variation in gene expression patterns in follicular lymphoma and the response to rituximab. Proc Natl Acad Sci USA 2003;100:1926-30 (Pubitemid 36254550)
66. De Jong D. Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. J Clin Oncol 2005;23:6358-63 (Pubitemid 46218847)
67. Lech-Maranda E, Baseggio L, Bienvenu J, et al. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large b-cell lymphoma. Blood 2004;103:3529-34 (Pubitemid 38525688)
68. Berglund M, Thunberg U, Roos G, et al. The interleukin-10 gene promoter polymorphism (-1082) does not correlate with clinical outcome in diffuse large b-cell lymphoma. Blood 2005;105:4894-5 (Pubitemid 40807321)
69. Domingo-Domenech E, Benavente Y, Gonzalez-Barca E, et al. Impact of interleukin-10 polymorphisms (- 1082 and -3575) on the survival of patients with lymphoid neoplasms. Haematologica 2007;92:1475-81 (Pubitemid 350144122)
70. Kube D, Hua TD, Kloss M, et al. The interleukin-10 gene promoter polymorphism -1087AG does not correlate with clinical outcome in non-Hodgkins lymphoma. Genes Immun 2007;8:164-7 (Pubitemid 46390915)
71. Lee JJ, Kim DH, Lee NY, et al. Interleukin-10 gene polymorphism influences the prognosis of t-cell non-Hodgkin lymphomas. Br J Haematol 2007;137:329-36 (Pubitemid 46650250)
72. Warzocha K, Ribeiro P, Bienvenu J, et al. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkins lymphoma outcome. Blood 1998;91:3574-81 (Pubitemid 28225722)
73. Seidemann K, Zimmermann M, Book M, et al. Tumor necrosis factor and lymphotoxinalfa genetic polymorphisms and outcome in pediatric patients with non-Hodgkins lymphoma: results from Berlin-Frankfurt-Munster trial nhl-bfm 95. J Clin Oncol 2005;23:8414-21
74. Juszczynski P, Kalinka E, Bienvenu J, et al. Human leukocyte antigens class ii and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. Blood 2002;100:3037-40
75. Nowak J, Kalinka-Warzocha E, Juszczynski P, et al. Association of human leukocyte antigen ancestral haplotype 8.1 with adverse outcome of non-Hodgkins lymphoma. Genes Chromosomes Cancer 2007;46:500-7 (Pubitemid 46449253)
76. Fitzgibbon J, Grenzelias D, Matthews J, et al. Tumour necrosis factor polymorphisms and susceptibility to follicular lymphoma. Br J Haematol 1999;107:388-91 (Pubitemid 29530230)
77. Gemmati D, Ongaro A, Tognazzo S, et al. Methylenetetrahydrofolatereductase c677t and a1298c gene variants in adult non-Hodgkins lymphoma patients: association with toxicity and survival. Haematologica 2007;92:478-85 (Pubitemid 350144293)
78. Hohaus S, Mansueto G, Massini G, et al. Glutathione-s-transferase genotypes influence prognosis in follicular non-Hodgkins lymphoma. Leuk Lymphoma 2007;48:564-9 (Pubitemid 46499175)
79. Hu LL, Wang XX, Chen X, et al. Bcrp gene polymorphisms are associated with susceptibility and survival of diffuse large b-cell lymphoma. Carcinogenesis 2007;28:1740-4 (Pubitemid 47289036)
80. Cerhan JR, Wang S, Maurer MJ, et al. Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood 2007;109:5439-46 (Pubitemid 46890567)
81. Han X, Zheng T, Foss FM, et al. Genetic polymorphisms in the metabolic pathway and non-Hodgkin lymphoma survival. Am J Hematol 2010;85:51-6
82. Armitage P, Berry G, Mathews JNS. Statistical methods in medical research. Wiley-Blackwell; 2001
83. Orsborne C, Byers R. Impact of gene expression profiling in lymphoma diagnosis and prognosis. Histopathology 2011;58:106-27
84. Zhang Y, Lan Q, Rothman N, et al. A putative exonic splicing polymorphism in the BCL6 gene and the risk of non-Hodgkin lymphoma. JNCI 2005;97:1616-18 (Pubitemid 41662716)
85. MacCuish JD, MacCuish NE. Clustering in bioinformatics and drug discovery. Chapman and Hall/CRC; 2010
86. Monti S, Savage KL, Kutok JL, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005;105:1851-61 (Pubitemid 40731764)
87. Ma S, Song X. Ranking prognosis markers in cancer genomic studies. Brief Bioinform 2011;12:33-40
88. Storey JD. The positive false discovery rate: a Bayesian interpretation and the q-value. Ann Stat 2003;31:2013-35 (Pubitemid 38293903)
89. Ma S, Huang J, Shi M, et al. Semiparametric prognosis models in genomic studies. Brief Bioinform 2010;11:385-93
90. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003;3:185-97 (Pubitemid 37443390)
91. Ma S, Huang J. Penalized feature selection and classification in bioinformatics. Brief Bioinform 2008;9:392-403
92. Ma S, Zhang Y, Huang J, et al. Identification of Non-Hodgkins lymphoma prognosis signatures using the CTGDR method. Bioinformatics 2010;26:15-21
93. Han X, Li Y, Huang J, et al. Identification of predictive pathways for non-Hodgkin lymphoma prognosis. Cancer Inform 2010;9:281-92
94. Peng G, Luo L, Siu H, et al. Gene and pathway-based second-wave analysis of genome-wide association studies. Eur J Hum Genet 2010;18:111-17
95. Wang K, Li M, Bucan M. Pathway-based approaches for analysis of genome wide association studies. Am J Hum Genet 2007;81:1278-83 (Pubitemid 350211456)
96. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. PNAS 2005;102:15545-50 (Pubitemid 41528093)
97. Efron B, Tibshirani R. On testing the significance of sets of genes. Ann Appl Stat 2007;1:107-29
98. Goeman JJ, van de Geer S, de Kort F, et al. A global test for groups of genes: testing association with a clinical outcome. Bioinformatics 2004;20:93-9 (Pubitemid 38088346)
99. Ma S, Shi M, Li Y, et al. Incorporating gene co-expression network in identification of cancer prognosis markers. BMC Bioinformatics 2010;11:271
100. Ma S, Kosorok MR, Huang J, et al. Incorporating higher-order representative features improves prediction in network-based cancer prognosis analysis. BMC Med Genomics 2011;4:5